(Q43572318)

24 November 2017

title

Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis (English)

1 reference

24 November 2017

1 reference

G Caro

1

1 reference

24 November 2017

D Getsios

2

1 reference

24 November 2017

J J Caro

3

1 reference

24 November 2017

G Raggio

4

1 reference

24 November 2017

M Burrows

5

1 reference

24 November 2017

L Black

6

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

24 November 2017

1 reference

24 November 2017

volume

21

1 reference

24 November 2017

issue

1

1 reference

24 November 2017

page(s)

12-19

1 reference

Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00130.X

Healthcare resource use and costs associated with migraine in a managed healthcare setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00130.X

Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00130.X

Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00130.X

Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00130.X

Sumatriptan. A pharmacoeconomic review of its use in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00130.X

Comparing dihydroergotamine mesylate and sumatriptan in the management of acute migraine. A retrospective cost-efficacy analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00130.X

Prevalence of migraine headache in Canada: a population-based survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00130.X

Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device: comparison with customary treatment in an open, longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00130.X

A within-patient comparison of subcutaneous and oral sumatriptan in the acute treatment of migraine in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00130.X

The Migraine ACE Model: Evaluating the Impact on Time Lost and Medical Resource Use

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00130.X

10.1046/J.1468-2982.2001.00130.X

21 January 2018

Identifiers

DOI

1 reference

24 November 2017

1 reference